COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

April 1, 2020

Study Completion Date

June 7, 2020

Conditions
Dysfunctional Uterine Bleeding
Interventions
DRUG

Pepti 3.6 mg

Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation

Trial Locations (5)

01133

Central Military Hospital, Kyiv

03039

LLC Medical Center, Kyiv

03148

Maternity Hospital no 3, Kyiv

04053

Center for Innovative Medical Technologies of the National Academy of Sciences, Kyiv

04112

City Clinical Hospital, Kyiv

All Listed Sponsors
lead

Peptigroupe Inc.

INDUSTRY

NCT04428684 - COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg | Biotech Hunter | Biotech Hunter